Fasching, P. A., Brucker, C., Decker, T., Engel, A., Göhler, T., Jackisch, C., . . . Wöckel, A. (2026). Real-world progression-free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study : cancer therapy and prevention. International journal of cancer, 159(1), . https://doi.org/10.1002/ijc.70397
Chicago-Zitierstil (17. Ausg.)Fasching, Peter Andreas, et al. "Real-world Progression-free Survival and Overall Survival in Patients with HR+/HER2− Advanced Breast Cancer Treated in First-line with Ribociclib, Endocrine Monotherapy or Chemotherapy: Results from the Observational RIBANNA Study : Cancer Therapy and Prevention." International Journal of Cancer 159, no. 1 (2026). https://doi.org/10.1002/ijc.70397.
MLA-Zitierstil (9. Ausg.)Fasching, Peter Andreas, et al. "Real-world Progression-free Survival and Overall Survival in Patients with HR+/HER2− Advanced Breast Cancer Treated in First-line with Ribociclib, Endocrine Monotherapy or Chemotherapy: Results from the Observational RIBANNA Study : Cancer Therapy and Prevention." International Journal of Cancer, vol. 159, no. 1, 2026, https://doi.org/10.1002/ijc.70397.